Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of BMS-354825 [dasatinib] in patients with solid tumors.

Trial Profile

A phase I study of BMS-354825 [dasatinib] in patients with solid tumors.

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2010

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Dec 2010 Actual patient number is 16 according to ClinicalTrials.gov.
    • 08 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top